Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Dexcom G7 CGM in critically ill adults after major abdominal surgery or solid organ transplant

Official title: Determining the Reliability and Accuracy of the Dexcom G7 Continuous Glucose Monitoring System in the ICU

Run by Institute for Clinical and Experimental Medicine · NCT07611721 · Data updated 2026-11-12

This study tests how accurately the Dexcom G7 continuous glucose monitor tracks glucose in ICU patients after major abdominal surgery or solid organ transplantation who need tight insulin control.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment62 (estimated)
SponsorInstitute for Clinical and Experimental Medicine
Government
Locations1 site (Prague)
StatusRecruiting
StartedJanuary 14, 2026
Main results expectedSeptember 2026
Study endsApril 2027
Registry record updatedMay 28, 2026
Trial IDNCT07611721 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 years or older in the ICU who require blood glucose monitoring for insulin therapy after major abdominal surgery or solid organ transplantation.

Probably not a fit

Patients who do not require tight insulin therapy or who cannot wear the sensor due to medical or physical considerations may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In this interventional study, critically ill adults in the ICU wearing two Dexcom G7 sensors will help determine how well the device measures glucose during insulin therapy after major abdominal surgery or organ transplantation. One sensor is blinded to avoid monitoring, while the other provides real-time data to guide insulin dosing. Patients will wear sensors for up to 10 days, with four glucose checks per day and daily SOFA scoring to correlate sensor readings with patient status. Calibration occurs only on the unblinded sensor using standard blood glucose meter readings. The study design includes ongoing integration with routine ICU care without altering standard workflows.

Why it matters

Potential benefit: If successful, Dexcom G7 could offer reliable, continuous glucose data to support insulin management in critically ill patients.

How similar studies have gone: Preliminary work with continuous glucose monitors in ICU settings has shown promise for accuracy, but this specific ICU post-surgical/organ transplant population is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 18 years or over
* Intensive care unit admission
* Requiring blood glucose monitoring for insulin therapy

Exclusion Criteria:

* High-dose ascorbic acid or acetaminophen \> 4g/day
* Physical or mental health condition precluding continuous wear of the continuous glucose monitor, as judged by the physician

Where it's running

  • Institute of Clinical and Experimental Medice
    Prague, Czechia
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.